SGLT2 Inhibitors: From Basic Physiology to Clinical Success
Symposium — Sunday, April 7, 2019 — 1:30 PM - 3:00 PM — Convention Center, Room W311B
Physiologists in Industry Committee — Chair: Romer Gonzalez Villalobos — Co-Chair: Paramita Pati
Cosponsored by AJP - Renal Physiology
Basic physiology experiments indicate that the sodium-glucose cotransporter 2 (SGLT2) is responsible for most glucose reabsorption in the kidneys, a key mechanism for glucose homeostasis. Based on this knowledge, SGLT2 inhibitors (SGLT2i) were developed to lower plasma glucose in diabetic patients. However, in addition to its glucose lowering effects, several large clinical trials showed that SGLT2i confer strong cardiovascular and possibly renal protection. These findings resulted in a multiplicity of ongoing efforts looking to expand the use of SGLT2i to other indications including heart failure and diabetic kidney disease. These observations make the SGLT2i an excellent example of the broad impact that the study of physiology continues to have in human medicine.
- The Basic Physiological Mechanisms of SGLT2 Inhibition
Scott Thompson — Div. of Nephrology-Hypertension, UCSD Sch. of Med.
- Empagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Maximilian von Eynatten — TA Metabolism Medicine, Boehringer INgelheim International GmbH
- Canagliflozin and Renal Outcomes in Type 2 Diabetes
Jennifer Davidson — Vice-President, Global medical Affairs Cardiovascular and Metabolism, Janssen Pharmaceuticals